Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – Equities researchers at SunTrust Banks reduced their FY2018 earnings per share (EPS) estimates for shares of Bellicum Pharmaceuticals in a note issued to investors on Wednesday, April 11th. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will earn ($3.33) per share for the year, down from their prior estimate of ($3.30). SunTrust Banks currently has a “Buy” rating and a $18.00 target price on the stock. SunTrust Banks also issued estimates for Bellicum Pharmaceuticals’ Q4 2018 earnings at ($0.82) EPS, FY2019 earnings at ($3.15) EPS, FY2020 earnings at ($2.96) EPS, FY2021 earnings at $0.20 EPS and FY2022 earnings at $0.64 EPS.
BLCM has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price objective (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. Citigroup lifted their price objective on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, February 16th. Wells Fargo upgraded shares of Bellicum Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price objective for the stock from $8.30 to $6.85 in a research note on Wednesday, April 11th. ValuEngine downgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research downgraded shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $17.98.
NASDAQ:BLCM opened at $8.97 on Monday. Bellicum Pharmaceuticals has a 12 month low of $5.02 and a 12 month high of $14.49. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.37 and a quick ratio of 8.37. The firm has a market cap of $301.48, a PE ratio of -3.16 and a beta of 0.47.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The company had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.08 million.
In related news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total transaction of $2,248,978.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 18.77% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of BLCM. Point72 Asset Management L.P. acquired a new position in Bellicum Pharmaceuticals during the third quarter valued at $4,723,000. Prosight Management LP acquired a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $2,534,000. Millennium Management LLC acquired a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $1,045,000. X Square Capital LLC acquired a new position in Bellicum Pharmaceuticals during the fourth quarter valued at $544,000. Finally, Schwab Charles Investment Management Inc. lifted its position in Bellicum Pharmaceuticals by 47.1% during the third quarter. Schwab Charles Investment Management Inc. now owns 131,217 shares of the biopharmaceutical company’s stock valued at $1,516,000 after purchasing an additional 41,995 shares during the period. Institutional investors own 54.58% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/17/suntrust-banks-comments-on-bellicum-pharmaceuticals-inc-s-fy2018-earnings-blcm.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.